EGFR degraders to treat cancer metastasis to the brain or CNS

MYPI2026003168A0Undetermined Publication Date: 2022-11-26C4 THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026003168
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-21
Filing Date
2022-05-26
Publication Date
2022-11-26
Patent Text Reader

Abstract

The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent. [Fig.2A]
Need to check novelty before this filing date? Find Prior Art